Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged ...
1 May 1999 in Journal of the Electrochemical Society
Advanced Parkinson disease (PD) is associated with treatment-related motor fluctuations and reduced ability to perform activities of daily living. Progression of non-motor symptoms and medication-induced adverse effects complicate focused approach to motor symptom management, frequently accelerating reduced quality of life. It is thus critical for clinicians to consider disease progression versus therapeutic contributions when balancing management decisions. Such an approach requires careful recognition of inflection points resulting from therapeutic decisions and should prompt consideration of reduced pharmacologic burden and increased reliance on non-pharmacologic strategies in advanced disease. The successful approach to advanced PD requires a multidisciplinary effort focused on improving the patient’s and family’s quality of life, sometimes requiring sacrifice of motor symptom benefit. Here, we emphasize management strategies in advanced PD, focusing on the need to balance the therapeutic approach across advancing motor symptoms, progressive non-motor features, and potential pharmacologic adverse effects.
Parkinson’s disease (PD) and Lewy Body Dementia (LBD) are defined by accumulation of alpha-synuclein (Asyn) fibrils within Lewy bodies (LBs) and Lewy neurites (LNs). The development of a Positron Emission Tomography (PET) tracer for quantifying Asyn fibrils would improve diagnostic accuracy and provide a biomarker for disease progression. We previously described radioligand [3H]Tg-1-90B, which binds to in vitro Asyn fibrils (PDB 2N0A) via interactions with residues Y39, S42 and K44. Here, we performed molecular docking studies with Tg1-90B and PD/LBD Asyn fibrils (PDB 8A9L), which predicts interactions with residues Y39 and K43 in a structurally distinct binding site. In radioligand binding assays, Tg-1-90B has moderate to high affinity (Kd 17.5 nM) for amplified LBD fibrils (PDB 8FPT), whose protofilament fold is highly similar to PD/LBD fibrils (PBD 8A9L). Autoradiography confirmed binding of [3H]Tg-1-90B to LBs in PD brain tissue. However, Tg-1-90B also binds to amyloid-beta fibrils in Alzheimer’s disease (AD) tissue, indicating insufficient selectivity for Asyn fibrils. These results indicate that Tg-1-90B binds to Asyn fibrils in PD tissue but needs further structural optimization. Binding assays with amplified LBD fibrils and autoradiography with postmortem PD tissue can guide further development of Asyn fibril PET ligands for PD/LBD.
6 December 2025 in Parkinsonism & Related Disorders
Parkinson's disease (PD) is clinically heterogenous. We previously identified a multi-domain classification of distinct PD subtypes in participants without dementia, yielding Motor Only, Psychiatric & Motor, and Cognitive & Motor subtypes. These PD subtypes may exhibit different rates of brain atrophy. We aim to determine baseline and longitudinal morphometric brain signatures of PD clinical subtypes and their relationship to behavioral change. 213 PD and 73 control participants completed T1-weighted structural MRIs and motor, cognitive, and psychiatric measures at baseline and every 1-3 years. We used FreeSurfer-v7.3 to obtain cortical thickness and brain volume measures, with manual edits as necessary. We used hierarchical linear models for longitudinal analyses-modeling time, subtype and their interaction; predictors include baseline age, motor symptom duration, sex, and education. Morphological brain MRI measures differentiate PD clinical subtypes at baseline, and the subtypes demonstrate different longitudinal rates of atrophy. The Motor Only subtype has preserved baseline morphometry and slow rate of atrophy, the Psychiatric & Motor has widespread baseline cortical thinning and slow rate of atrophy, and the Cognitive & Motor has baseline global and regional volume loss and fast rate of atrophy. Additionally, baseline morphometric measures predict longitudinal behavioral change within the Cognitive & Motor subtype. Multi-domain PD clinical subtypes exhibit distinct baseline brain morphometric patterns and predictable longitudinal volumetric changes that substantiate previous observations of differential risks of progression, dementia, and death. These findings suggest underlying biological differences across subtypes that may help inform clinical expectations and guide clinical trial design.
Alpha-synuclein (asyn) fibril accumulation is the defining feature of Parkinson disease and is a target for disease-modifying treatments. One therapeutic strategy to reduce fibril accumulation is inhibition of asyn fibril growth. We developed a sensitive fluorescence-based fibril growth assay to screen for small molecule inhibitors. After validating the inhibition assay using a previously identified inhibitor, epigallocatechin-3-gallate, we identified compound 1 as a lead for inhibition of fibril growth. We analysed structure-activity relationships with analogs of 1 to optimize inhibition potency. Our results identified two dimethoxyphenyl piperazine analogs with more potent inhibition of in-vitro assembled fibrils, which were further validated with orthogonal assays including kinetic measurements of fibril concentration with Thioflavin T. These analogs also inhibited the growth of asyn fibrils amplified from Lewy Body Disease brain tissue, further validating the inhibitor screening assay. Molecular docking studies indicate that these compounds can bind to the fibril ends, suggesting a potential capping mechanism through which these compounds inhibit the sequential association of monomeric asyn required for fibril growth.